Adrian Rawcliffe - 12 Jan 2022 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADAP	Option to purchase Ordinary Shares	Award	$0	+4,690,224		$0.000000	4,690,224	12 Jan 2022	Ordinary Shares	4,690,224	$0.6000	Direct	F1, F2
transaction	ADAP	Option to purchase Ordinary Shares	Award	$0	+1,047,480		$0.000000	1,047,480	12 Jan 2022	Ordinary Shares	1,047,480	$0.001400	Direct	F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The exercise price was converted from GBP0.44 based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2	Exercisable as to 1,172,556 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 97,710 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 97,818 Ordinary Shares on January 12, 2026.
F3	The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4	Exercisable as to 261,870 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 261,870 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026.
F5	The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.